Inauhzin is primarily used in cancer research due to its ability to activate the p53 pathway, a critical tumor suppressor mechanism in cells. It helps induce apoptosis in cancer cells without causing significant damage to normal cells, making it a promising candidate for targeted cancer therapies. Unlike some other p53-activating compounds, Inauhzin does not cause DNA damage, which reduces the risk of secondary mutations or side effects. It has shown effectiveness in laboratory studies against various cancer types, including those resistant to conventional chemotherapy. Additionally, Inauhzin enhances the effects of other anticancer agents, suggesting potential for use in combination treatments. Its role in modulating cellular senescence and inhibiting cancer cell proliferation continues to be explored in preclinical models.